ERBB2 and breast carcinoma: This potent bystander effect is observed with trastuzumab deruxtecan due to its highly membrane-permeable payload, and explains its efficacy in treating tumors with HER2 heterogeneity, resulting in approval in patients with previously treated unresectable or metastatic ‘HER2-low’ breast cancer [30,31].